Application
Amenamevir may be used in laboratory studies to investigate the mechanisms of viral replication, particularly in the context of herpes simplex virus (HSV) and varicella-zoster virus (VZV) infections. It may also be used as a model compound in the development of other antiviral agents, helping researchers understand the structure-activity relationship of helicase-primase inhibitors.
Biochem/physiol Actions
Amenamevir (ASP2151) is an orally active and potent helicase-primase complex inhibitor with equipotency against viral DNA replication of varicella-zoster virus (VZV Ellen EC50/EC90 = 47/460 nM) and herpes simplex virus (EC50/EC90 = 36/230 nM using HSV-1 (KOS) & 28/460 nM using HSV-2 (G)). This antiherpetic agent prevents the replication of these viruses. Amenamevir is much more potent (EC50 38-100 nM) than aciclovir (EC50 = 1.3-2.7 µM) against all VZV strains tested and is active against aciclovir-resistant VZV. This oxadiazolephenyl derivative is 14-times more potent than valaciclovir in a zosteriform-spread model among mice infected with HSV-1 in vivo (EC50 = 1.9 vs. 27 mg/kg, respectively, via twice daily p.o.).
| Quality Level | 100 |
| assay | ≥98% (HPLC) |
| form | powder |
| color | white to beige |
| solubility | DMSO: 2 mg/mL, clear |
| storage temp. | 2-8°C |
| SMILES string | O=C(N(CC(NC1=CC=C(C=C1)C2=NOC=N2)=O)C3=C(C=CC=C3C)C)C4CCS(CC4)(=O)=O |
